Actively Recruiting
Long-term Safety and Efficacy Study of Oral NNZ-2591 in Children with Phelan-McDermid Syndrome
Led by Neuren Pharmaceuticals Limited · Updated on 2026-10-19
180
Participants Needed
11
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety, tolerability, and effectiveness of NNZ-2591 in children with Phelan-McDermid Syndrome in this Phase 3 open-label extension study. The trial focuses on pediatric participants who have previously taken part in related studies and aims to better understand the impact of this treatment over an extended period. Participants who qualify will take NNZ-2591 orally twice daily for a year during the Treatment Period. After completing this 52-week phase, there is a 2-week safety follow-up period to monitor any lasting effects or side effects. The study is designed to assess how well participants tolerate the treatment and to observe any changes in their symptoms. During the study, participants will undergo assessments to confirm eligibility, establish baseline health and symptom severity, and monitor safety through adverse event tracking, ECG, vital signs, and laboratory tests. Researchers will also evaluate treatment effects using specific behavioral and severity scales at 3 and 12 months. The total time commitment for each participant is up to 56 weeks, including treatment and follow-up.
CONDITIONS
Brief Title
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Research Team
M
Medical Information Lead
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here